DNA methylation as a biomarker for preeclampsia

Area of Science:

• Obstetrics and Gynecology
• Epigenetics
• Perinatal Medicine

Background:

• Preeclampsia is a major cause of maternal and infant mortality and morbidity.
• It also increases the long-term risk of cardiovascular disease in mothers and offspring.
• Current detection methods are insufficient for timely prevention and treatment.

Purpose of the Study:

• To identify unique DNA methylation patterns in maternal and fetal tissues associated with preeclampsia.
• To explore these patterns as potential biomarkers for predicting preeclampsia and its inheritance.
• To advance early detection and intervention strategies for preeclampsia.

Main Methods:

• Prospective study of 55 nulliparous women in their first trimester.
• Genome-wide DNA methylation analysis of maternal white blood cells and placental chorionic tissue.
• Comparison between normotensive pregnant women and those who developed preeclampsia.

Main Results:

• Significant differences in DNA methylation were found at 207 CpG sites in maternal white blood cells.
• These methylation changes included both gains and losses.
• Approximately 75% of these differentially methylated sites were also found in fetal-derived chorionic tissue.

Conclusions:

• This study identified maternal and common fetal epigenetic targets for preeclampsia.
• These represent potential biomarkers for early preeclampsia detection.
• Findings may enable diagnosis before clinical symptoms and prevention of long-term complications.